CAS: 1609660-14-1
(2Z,4E)-5-[(1S)-3-(Hexylthio)-1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl]-3-methyl-2,4-pentadienoic Acid-d13
Prodotto ControllatoCAS:1609660-14-1
Applications (2Z,4E)-5-[(1S)-3-(Hexylthio)-1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl]-3-methyl-2,4-pentadienoic Acid-d13 is the isotope labelled analog of (2Z,4E)-5-[(1S)-3-(Hexylthio)-1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl]-3-methyl-2,4-pentadienoic Acid (H298050); an analog of …
Formula:
C21H19D13O4S
Colore e forma:
Neat
Peso molecolare:
393.62
Ref: TR-H298052
10mg | 2.174,00 € |
Consegna stimata in Stati Uniti, il Martedì 28 Gennaio 2025
(2Z,4E)-5-[(1S)-3-(Hexylthio)-1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl]-3-methyl-2,4-pentadienoic acid
CAS:1609660-14-1
Please enquire for more information about (2Z,4E)-5-[(1S)-3-(Hexylthio)-1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl]-3-methyl-2,4-pentadienoic acid including the price, delivery time and more …
Formula:
C21H32O4S
Purezza:
Min. 95%
Peso molecolare:
380.5 g/mol
Ref: 3D-JPC66014
10mg | Prezzo su richiesta | ||
25mg | Prezzo su richiesta | ||
50mg | Prezzo su richiesta |
Consegna stimata in Stati Uniti, il Lunedì 27 Gennaio 2025
AS6
CAS:1609660-14-1
AS6 is an ABA-induced PYL-PP2C interaction antagonist in a dose-dependent manner.
Formula:
C21H32O4S
Purezza:
98%
Colore e forma:
Solid
Peso molecolare:
380.54
Ref: TM-T23756
25mg | 1.967,00 € | ||
50mg | 2.600,00 € | ||
100mg | 3.460,00 € |
Consegna stimata in Stati Uniti, il Martedì 18 Febbraio 2025
(2Z,4E)-5-[(1S)-3-(Hexylthio)-1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl]-3-methyl-2,4-pentadienoic Acid
CAS:1609660-14-1
Applications (2Z,4E)-5-[(1S)-3-(Hexylthio)-1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl]-3-methyl-2,4-pentadienoic Acid, an analog of Abscisic Acid (A110000), is designed as an antagonist of …
Formula:
C21H32O4S
Colore e forma:
White to Off-White Solid
Peso molecolare:
424.468
Ref: TR-H298050
5mg | Fuori produzione | Richiedi informazioni | |
50mg | Fuori produzione | Richiedi informazioni |